Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Stopped The study was closed to enrollment when it became clear that enrollment was too slow to complete the full enrollment target within the time frame allowed.

Conditions

• Renal Cell Carcinoma

Interventions

• DRUG: Sorafenib Escalated Dose
• DRUG: Sorafenib Standard Dose

Sponsor

Accelerated Community Oncology Research Network

Collaborators

• [object Object]